Senseonics Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $48.5M+116.0% YoYTTM through 30 Jun 2026
Net Income -$109.4MTTM through 30 Jun 2026
Free Cash Flow -$97.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 44.8% |
| EBITDA Margin | -219.4% |
| Operating Margin | -193.5% |
| Net Margin | -225.3% |
Returns
-113.2%ROE
-54.7%ROA
Balance Sheet Health
Debt / Equity0.58x
Current Ratio4.83x
Net Debt-$58.7Mnet cash position
Cash & Equivalents$44.8M
Quality Metrics
Altman Z-Score-5.69
Piotroski F-Score6 / 9
FCF Margin-200.0%
Rule of 40-171.9
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $35.3M
Diluted EPS-$2.24TTMFY2025: $-1.66
Dividend
No dividend
Capital Allocation
R&D Spend$36.8M
Capex Intensity2.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Diabetes Products and Services | $35.3M | +56.9% | View detailsSenseonics expects full-year 2026 global net revenue to be approximately $60 million to $64 million, representing year-over-year growth of 70% to 82%. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.